Research programme: cannabinoid therapeutics - GB Sciences

Drug Profile

Research programme: cannabinoid therapeutics - GB Sciences

Alternative Names: BCTC - Makai Biotechnology; TRPV1 inhibitors

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Hawaii
  • Developer GB Sciences; Makai Biotechnology
  • Class Analgesics; Anti-inflammatories; Antiparkinsonians; Cannabinoids; Cardiovascular therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Immunomodulators; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Heart failure; Inflammation; Neuropathic pain; Parkinson's disease

Most Recent Events

  • 22 Jun 2018 GB Sciences files US and PCT non-provisional patent applications for myrcene-containing complex mixtures for Pain and Heart disorders
  • 10 Apr 2018 Gb Sciences announces intention to submit exploratory IND to the US FDA for Parkinson's disease
  • 10 Apr 2018 GB Biosciences plans a first in human phase 0 trial for Parkinson's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top